Germany tells Israeli government to stop West Bank settlement construction
Germany "firmly rejects the Israeli government's announcements regarding the approval of thousands of new housing units in Israeli settlements in the West Bank," said a foreign ministry spokesperson in a statement.
Plans for the "E1" settlement and the expansion of Maale Adumim would further restrict the mobility of the Palestinian population in the West Bank by splitting it in half and cutting the area off from East Jerusalem, said the spokesperson.
Israeli Finance Minister Bezalel Smotrich announced on Thursday that work would start on the long-delayed settlement, a move that his office said would "bury" the idea of a Palestinian state.
In a statement, Smotrich's spokesperson said the minister had approved the plan to build 3,401 houses for Israeli settlers between an existing settlement in the West Bank and Jerusalem.
Germany has repeatedly warned the Israeli government to stop settlement construction in the West Bank, which violates international law and U.N. Security Council resolutions.
Such moves complicate steps towards a negotiated two-state solution and end to Israeli occupation of the West Bank, said the spokesperson.
(Writing by Miranda Murray, Editing by Rachel More)
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Lennar (LEN) Rises As Market Takes a Dip: Key Facts
Lennar (LEN) closed at $131.95 in the latest trading session, marking a +1.15% move from the prior day. This move outpaced the S&P 500's daily loss of 0.29%. Elsewhere, the Dow saw an upswing of 0.08%, while the tech-heavy Nasdaq depreciated by 0.4%. Heading into today, shares of the homebuilder had gained 18.92% over the past month, outpacing the Construction sector's gain of 6.32% and the S&P 500's gain of 3.25%. The upcoming earnings release of Lennar will be of great interest to investors. In that report, analysts expect Lennar to post earnings of $2.14 per share. This would mark a year-over-year decline of 45.13%. At the same time, our most recent consensus estimate is projecting a revenue of $9.07 billion, reflecting a 3.7% fall from the equivalent quarter last year. For the full year, the Zacks Consensus Estimates project earnings of $9.04 per share and a revenue of $35.22 billion, demonstrating changes of -34.78% and -0.63%, respectively, from the preceding year. It's also important for investors to be aware of any recent modifications to analyst estimates for Lennar. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Lennar is holding a Zacks Rank of #5 (Strong Sell) right now. From a valuation perspective, Lennar is currently exchanging hands at a Forward P/E ratio of 14.43. This expresses a premium compared to the average Forward P/E of 11.73 of its industry. We can also see that LEN currently has a PEG ratio of 5.54. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Building Products - Home Builders industry held an average PEG ratio of 2.53. The Building Products - Home Builders industry is part of the Construction sector. Currently, this industry holds a Zacks Industry Rank of 229, positioning it in the bottom 8% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lennar Corporation (LEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Merck KGaA ventures into new territory in the US
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck KGaA has been making new moves to propel itself into becoming what CEO Belén Garijo described as a 'globally diversified science and technology powerhouse.' Most recently, the company closed its $3.4 billion acquisition of Pfizer spinout SpringWorks Therapeutics, which will help it stake a claim in the rare tumor space. And in general, it's all about 'doubling down' on R&D and building the company's U.S. footprint, said Miguel Fernández Alcalde, president of EMD Serono, Merck KGaA's healthcare business in the U.S. and Canada. Germany-based Merck KGaA has undergone a number of transformations throughout its deep history. In 2022, the company restructured into three distinct business units including one focused on the life sciences sector and manufacturing services. But with the contract manufacturing blitz of the COVID-19 pandemic era fading, the company is refocusing. EMD Serono relocated its U.S. headquarters to Boston's Seaport district to place itself squarely in the thick of the region's most innovative 'biotechs, startups, academia and scientists,' Fernández Alcalde said. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization." Miguel Fernández Alcalde President, EMD Serono Merck KGaA also elevated its global head of R&D and chief medical officer of its healthcare business, Dr. Danny Bar-Zohar, to healthcare CEO. 'That tells you that the company's moving along in the direction of doubling down on R&D,' Fernández Alcalde said. Fernández Alcalde's appointment to president of EMD Serono in December is also part of the company's overall quest to build its U.S. footprint and bolster R&D through external deals. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization,' he said. 'I do think we have lots of opportunities in the U.S. ecosystem and U.S. market. My job and my vision and ambition is to really untap all those things that we have ahead of us.' A pharmacist by trade, Fernández Alcalde has been with Merck KGaA since 2014, serving most recently as EMD Serono's chief operating officer. 'That gave me a lot of knowledge and understanding of the business of the company in the States and the teams, the dynamics, the culture, but also the U.S. [healthcare] ecosystem,' he said. Driving dealmaking Central to Fernández Alcalde's role is supplementing the company's current pipeline through external innovation investments, including more strategic in-licensing and co-development opportunities. The SpringWorks acquisition put the company on track to generate at least 50% of its future launch assets from external companies, compared to roughly 10%-15% just 18 months ago. 'It's easily a fivefold increase in our ambition from external innovation,' Fernández Alcalde said. In terms of what kinds of deals they're targeting, Fernández Alcalde said several factors are at play. 'We are not looking [for] the $40 billion type of acquisition,' he said. Nor will they chase first-in-class potential blockbusters with never-explored mechanisms of action. Instead, they'll target smaller deals with the 'right risk balance' for their pipeline. He pointed to the SpringWorks acquisition as an example, which not only adds two FDA-approved drugs to its portfolio, but also a 'runway of three to five years of nice growth' in the form of several clinical-phase pipeline candidates. 'These areas where we have deep, good science [and a] validated proof of concept or an about-to-be-validated proof of concept where the mechanism of action is already validated, is something we are interested in,' he said. The company will take a similar approach when it comes to therapeutic areas by branching out within reason. 'We are not sticking to the [therapeutic areas] we have today, but we are not going to go wild, either,' he said. Rather, they'll look for specialties that are 'adjacent' and 'logical' in terms of what they've been historically known for, such as oncology and neurology/immunology. Again, he pointed to the SpringWorks acquisition as an example and noted that some might ask what track record EMD Serono or Merck KGaA has in rare tumors. 'The answer is zero. But we do know how to commercialize,' he said. Plus, 'it's in an adjacent area of oncology.' Fernández Alcalde is also thinking globally, intending to follow good science wherever it leads and consider deals from around the world. 'We couldn't care less about where that science is coming from, whether it's China, my home country Spain, the U.S. or South Africa,' he said. 'If we think that science will help patients … we will definitely think about it.' Recommended Reading Let's make a deal? Big Pharma execs express varying views on their M&A future
Yahoo
an hour ago
- Yahoo
2025 balance press conference: Highest turnover in company history
In his 21st and last balance press conference as chairman of the board, Hans-Joachim Watzke looked back to the very beginning, with a loss of 54 million euros and a turnover of just 75 million euros, before turning to the current figures and emphasising: 'We have already achieved the benchmark turnover of 500 million euros, and now, after 509 million last year, we have reached the highest turnover in our history with 526 million euros. It has been a very successful year for us.' The same goes for the club's sporting performance in some respects: 'When you consistently qualify for the Champions League over ten years' - as one of only seven clubs in the whole of Europe to do so - 'that is quite exceptional!' Compared to the previous year (509 million euros), Borussia Dortmund - the only listed Bundesliga team - increased its turnover in the period 1 July 2024 to 30 June 2025 by 3.32 per cent, to 526 million euros. The final net profit was 10.5 million euros before tax and 6.5 million euros after tax, which falls within the predictions made before the season. The management board also reported a positive free cash flow of 21 million euros, with managing director Thomas Treß reporting a 'good, stable result.' Existing credit lines of 75 million euros had not been required by the reporting date of 30.6.2025. As a result of reaching the quarter-finals of the UEFA Champions League, the club's goals in terms of both sporting and economic performance were exceeded. The new format of the competition also meant that there were seven sold out home games (compared to six the previous year), with the associated additional revenue from ticketing. A further driver of revenue was the club's participation in the FIFA Club World Cup this summer. According to Treß's report, these revenues amounted to 33.9 million euros in the financial year 2024/25. In the tournament held in the USA, BVB reached the quarter-final, which took place on 5 July 2025. This was offset by BVB's early departure from the DFB Cup in the second round, and reduced transfer revenues compared to the previous year, when Jude Bellingham transferred to Real Madrid. Last season, Niclas Füllkrug and Donyell Malen left the club for significantly lower sums. Jamie Gittens' transfer to Chelsea FC falls in the new financial year 2025/26. Revenues from merchandising were also lower than in the year when, among other things, BVB profited from the hype surrounding their participation in the Champions League Final. 'We don't want to reinvent Borussia Dortmund, we want to develop it. We still have an incredible amount of potential and are capable of gaining the support of even more people and partners,' said managing director Carsten Cramer, emphasising: 'We are much, much more than just a football club.' A club which is conscious of its own social and ecological responsibility. Thomas Treß announced: 'We have set ourselves the goal of becoming climate neutral by 2040.' Together with the supervisory board, the management board wants to reiterate its suggestion of distributing a dividend of six cents per share at the general meeting in November. 'It is important to give a signal of dividend continuity to shareholders, even if the dividend uses up the entire annual net profit,' said managing director Thomas Treß. Boris Rupert
